Email this article News in immunotherapy for metastatic melanoma: prolgolimab in clinical practice (authors' experience)
- Authors: Oganesyan L.V.1,2, Karnaukhov N.S.2, Feoktistova P.S.2
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- Loginov Moscow Clinical Scientific Center
- Issue: Vol 25, No 3 (2023)
- Pages: 325-328
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/148898
- DOI: https://doi.org/10.26442/18151434.2023.3.202382
- ID: 148898
Cite item
Full Text
Abstract
The incidence of skin melanoma is growing globally and in Russia. Also, the proportion of patients with advanced skin melanoma prevails. Introduction into clinical practice of a novel group of immunological drugs (anti-CTLA4 and anti-PD-1) for metastatic melanoma increased the time to disease progression and patients' life expectancy. Prolgolimab is a PD-1 inhibitor, a new domestic drug that is effective and safe in treating metastatic melanoma. The article presents authors' experience with prolgolimab. When used in the first-line treatment of metastatic melanoma, this drug achieved long-term stabilization of the disease. The drug showed good tolerability, including in patients with severe comorbidity.
Full Text
##article.viewOnOriginalSite##About the authors
Liana V. Oganesyan
Russian Medical Academy of Continuous Professional Education; Loginov Moscow Clinical Scientific Center
Author for correspondence.
Email: liana15.94@mail.ru
ORCID iD: 0000-0001-7564-7472
graduate student, oncologist
Russian Federation, MoscowNikolay S. Karnaukhov
Loginov Moscow Clinical Scientific Center
Email: editor@omnidoctor.ru
ORCID iD: 0000-0003-0889-2720
cand. sci. (med.)
Russian Federation, MoscowPolina S. Feoktistova
Loginov Moscow Clinical Scientific Center
Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-0340-7119
cand. sci. (med.)
Russian Federation, MoscowReferences
- Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC Suppl. 2013;11(2):81-91. doi: 10.1016/j.ejcsup.2013.07.012
- Харкевич Г.Ю., Демидов Л.В. Эффективность ниволумаба в лечении метастатической меланомы. Злокачественные опухоли. 2017;3:62-9 [Kharkevich GY, Demidov LV. Efficacy of nivolumab in advanced melanoma. Malignant Tumours. 2017;3:62-9 (in Russian)]. doi: 10.18027/2224-5057-2017-7-3-62-69
- The Global Cancer Observatory. December, 2020. Available at: https://gco.iarc.fr/today/fact-sheets-cancers. Accessed: 05.08.2023.
- Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019 [Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii v 2018 godu. Pod red. AD Kaprina, VV Starinskogo, GV Petrovoi. Moscow: MNIOI im. P.A. Gertsena − filial FGBU «NMITs radiologii» Minzdrava Rossii, 2019 (in Russian)].
- Орлова К.В., Федянин М.Ю., Симаненков К.Э., и др. Эффективность 1-й линии терапии пролголимабом у больных метастатической меланомой в реальной клинической практике: промежуточные результаты наблюдательного исследования FORA «FOrteca Real practice Assessment». Современная Онкология. 2022;24(4):413-25 [Orlova KV, Fedyanin M, Simanenkov KE, et al. Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study. Journal of Modern Oncology. 2022;24(4):413-25(in Russian)]. doi: 10.26442/18151434.2022.4.202035
- Румянцев А.Г., Тюляндин С.А. Эффективность ингибиторов контрольных точек иммунного ответа в лечении солидных опухолей. Практическая онкология. 2016;17(2):74-89 [Rumyantsev AA, Tjulandin SA. Efficacy of immune checkpoints inhibitors in the treatment of solid tumors. Prakticheskaya onkologiya = Practical Oncology. 2016;17(2):74-89 (in Russian)].
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535-46. doi: 10.1056/NEJMoa1910836
- Long GV, Atkinson V, Menzies AM, et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the Anti-PD1 Brain Collaboration (ABC). J Clin Oncol. 2017; 35(15 suppl):9508. doi: 10.1200/JCO.2017.35.15_suppl.9508
- Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-30. doi: 10.1056/NEJMoa1412082
- Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17(7):943-55. doi: 10.1016/S1470-2045(16)30126-7
- Строяковский Д.Л. Клиническое исследование MIRACULUM: результаты эффективности пролголимаба при метастатической меланоме на протяжении 3 лет наблюдения. Петербургский международный онкологический форум «Белые ночи». 2021 [Stroiakovskii D.L. Klinicheskoe issledovanie MIRACULUM: rezul'taty effektivnosti prolgolimaba pri metastaticheskoi melanome na protiazhenii 3 let nabliudeniia. Peterburgskii mezhdunarodnyi onkologicheskii forum «Belye nochi». 2021 (in Russian)].
- Tjulandin SA, Fedyanin M, Demidov LV, et al. Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma. Annals of Oncology. 2019;30:xi44. doi: 10.1093/annonc/mdz451.027
- Tjulandin S, Demidov L, Moiseyenko V, et al. Novel PD-1 inhibitor prolgolimab: expanding nonresectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. doi: 10.1016/j.ejca.2021.02.030
